Anti-Inflammatory Therapies for Atopic Dermatitis: A New Era in Targeted Treatment
Open Access
- 16 July 2025
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (14) , 5053
Abstract
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition characterized by intense pruritus and a significant impact on a patient’s quality of life. Despite advancements in understanding AD pathophysiology, there remains a critical need for innovative therapeutic options to better manage this debilitating disease. This review focuses on the evolving landscape of biological therapies for AD, offering insights into their role, mechanisms of action, and potential to revolutionize patient care. In this review, we explore the underlying immunological mechanisms of AD, particularly the role of cytokines and immune pathways implicated in the disease, and how targeted biological therapies modulate these pathways. Current FDA- and EMA-approved biologics, such as Dupilumab, are also discussed in terms of their mechanisms of action, efficacy, and safety. Additionally, we compare their effectiveness, highlighting the benefits and limitations observed in clinical practice. Emerging biological therapies currently under development offer new hope, with innovative targets like IL-13, IL-31, and thymic stromal lymphopoietin (TSLP) representing promising avenues for intervention. We also delve into personalized medicine, emphasizing the importance of biomarkers for predicting treatment response and stratifying AD patients to optimize therapeutic outcomes. Moreover, the synergistic potential of combining biologics with traditional therapies is reviewed, along with a discussion of the challenges involved, including safety, long-term efficacy, and patient adherence. We address the future direction of AD treatment, including microbiome-targeting biologics and the development of next-generation immune modulators. We highlight a new era of targeted treatment possibilities for this complex condition.Keywords
Funding Information
- Department of Molecular and Cellular Biology of Wroclaw Medical University (SUBZ.D260.25.027)
This publication has 156 references indexed in Scilit:
- Clinical Presentation of Atopic Dermatitis2017
- Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2Journal of Molecular Biology, 2017
- Atopic dermatitis and filaggrinCurrent Opinion in Immunology, 2016
- What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability studyBritish Journal of Dermatology, 2015
- IL-36γ (IL-1F9) Is a Biomarker for Psoriasis Skin LesionsJournal of Investigative Dermatology, 2015
- Atopic Dermatitis: Natural History, Diagnosis, and TreatmentISRN Allergy, 2014
- Epidemiology of Atopic Dermatitis and Atopic March in ChildrenImmunology and Allergy Clinics of North America, 2010
- OX40-OX40L interactions: a promising therapeutic target for allergic diseases?Journal of Clinical Investigation, 2007
- Patient perspectives on the management of atopic dermatitisJournal of Allergy and Clinical Immunology, 2006
- Immunological differences between intrinsic and extrinsic types of atopic dermatitisClinical & Experimental Allergy, 2003